195 related articles for article (PubMed ID: 34277452)
1. Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.
Lv L; Sun X; Wu Y; Cui Q; Chen Y; Liu Y
Front Oncol; 2021; 11():707285. PubMed ID: 34277452
[TBL] [Abstract][Full Text] [Related]
2. Bruton's tyrosine kinase inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A meta-analysis and systematic review.
Guo HP; Dang XL; Kang L; Liu C; Liu XW
World Neurosurg; 2024 Apr; ():. PubMed ID: 38641241
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis.
Lv L; Wu Y; Shi H; Sun X; Deng Z; Huo H; Li R; Liu Y
Cancer Immunol Immunother; 2023 Jan; 72(1):211-221. PubMed ID: 35796863
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of BTKis in Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.
Zhang Y; Ye J; Chen H; Zhou D; Ji C
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473226
[TBL] [Abstract][Full Text] [Related]
5. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
Hou K; Yu Z; Jia Y; Fang H; Shao S; Huang L; Feng Y
Crit Rev Oncol Hematol; 2020 Aug; 152():103010. PubMed ID: 32540781
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.
Liu J; Guo J; Sun X; Liu Y; Gao C
Front Oncol; 2021; 11():799721. PubMed ID: 35096600
[TBL] [Abstract][Full Text] [Related]
8. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
[No Abstract] [Full Text] [Related]
9. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
[TBL] [Abstract][Full Text] [Related]
10. Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data.
Zhou J; Wang Z; Wang H; Cao Y; Wang G
Front Pharmacol; 2023; 14():1331844. PubMed ID: 38328579
[No Abstract] [Full Text] [Related]
11. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis.
Du J; Han X; Lin S; Qiu C; Zhu L; Huang Z; Hou J
Front Med (Lausanne); 2021; 8():732727. PubMed ID: 34805202
[No Abstract] [Full Text] [Related]
15. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
17. East Asian Herbal Medicine to Reduce Primary Pain and Adverse Events in Cancer Patients : A Systematic Review and Meta-Analysis With Association Rule Mining to Identify Core Herb Combination.
Jo HG; Seo J; Choi S; Lee D
Front Pharmacol; 2021; 12():800571. PubMed ID: 35111066
[No Abstract] [Full Text] [Related]
18. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Ball S; Das A; Vutthikraivit W; Edwards PJ; Hardwicke F; Short NJ; Borthakur G; Maiti A
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):87-97.e5. PubMed ID: 31787589
[TBL] [Abstract][Full Text] [Related]
19. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
[TBL] [Abstract][Full Text] [Related]
20. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
